Physician profile
Alyssa Crowe
NPI 1336645035
$1,122.68
in general payments reported to CMS, 2019-2025
14 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $366 · 2023: $461 · 2024: $188 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $692 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $691.55 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $402.27 | 2022-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2022 | |
| Medtronic, INC. | $124.99 | 2023 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $112.16 | 2022-2023 | Andexxa, Farxiga |
| Amgen INC. | $80.06 | 2022-2024 | Repatha |
| Abbott Laboratories | $70.90 | 2023-2024 | Cardiomems |
| Novartis Pharmaceuticals Corporation | $68.82 | 2022-2024 | |
| Boston Scientific Corporation | $37.10 | 2022 | |
| Paratek Pharmaceuticals, INC. | $18.88 | 2025 | Xhance, Nuzyra |
| Janssen Pharmaceuticals, INC | $17.72 | 2023 | Xarelto |
| Heartflow, INC. | $17.66 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.72 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.27 | 2023 | Jardiance |
| Novo Nordisk INC | $14.14 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Crowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.